Axovant Sciences (AXON) Hits New 1-Year High and Low at $1.11

Axovant Sciences (NASDAQ:AXON) shares hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $1.11 and last traded at $1.13, with a volume of 284498 shares. The stock had previously closed at $1.15.

Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Wednesday, January 31st. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. Finally, Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price target on the stock in a report on Wednesday, January 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.61.

The firm has a market cap of $127.19, a price-to-earnings ratio of -0.62 and a beta of -0.40. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.58 and a current ratio of 4.58.

In other news, Director George Bickerstaff acquired 25,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was acquired at an average price of $1.50 per share, with a total value of $37,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 72.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new position in Axovant Sciences during the third quarter valued at $117,000. Wells Fargo & Company MN lifted its position in Axovant Sciences by 135.6% during the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 30,905 shares during the period. Virtus Fund Advisers LLC purchased a new position in Axovant Sciences during the fourth quarter valued at $349,000. Hikari Power Ltd purchased a new position in Axovant Sciences during the fourth quarter valued at $377,000. Finally, Alliancebernstein L.P. lifted its position in Axovant Sciences by 108.8% during the fourth quarter. Alliancebernstein L.P. now owns 108,600 shares of the biotechnology company’s stock valued at $572,000 after buying an additional 56,600 shares during the period. 93.03% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3371586/axovant-sciences-axon-hits-new-1-year-high-and-low-at-1-11.html.

About Axovant Sciences

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.27 Earnings Per Share Expected for FNB Co.  This Quarter
$0.27 Earnings Per Share Expected for FNB Co. This Quarter
Bytom  Price Down 12.2% Over Last 7 Days
Bytom Price Down 12.2% Over Last 7 Days
DigixDAO 24 Hour Trading Volume Tops $1.59 Million
DigixDAO 24 Hour Trading Volume Tops $1.59 Million
Viuly  Price Hits $0.0070 on Major Exchanges
Viuly Price Hits $0.0070 on Major Exchanges
Superior Energy Services, Inc.  Expected to Post Earnings of -$0.22 Per Share
Superior Energy Services, Inc. Expected to Post Earnings of -$0.22 Per Share
Brokerages Anticipate Finish Line, Inc.  Will Post Quarterly Sales of $422.09 Million
Brokerages Anticipate Finish Line, Inc. Will Post Quarterly Sales of $422.09 Million


© 2006-2018 Ticker Report. Google+.